CV risk in patients with type 2 diabetes and CVD: getting to the heart of diabetes

Listen to our multidisciplinary panel of experts as they discuss the prevention of CV events in patients with both type 2 diabetes and CVD.

  • Cost: free


This webinar has been developed in partnership with the Australian Diabetes Society.

This program was funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.




It is recommended that 1 CPD hour be recorded for the purposes of self-directed CPD.



Over the last few years, the management of type 2 diabetes has rapidly grown more complex. Recent developments include new medicines, emerging clinical trial results that provide cardiovascular (CV) outcome data related to blood glucose-lowering medicines, and an update to clinical guidelines. Now, more than ever, a clear, stepped approach is necessary to navigate the plethora of options available and reduce risk of microvascular and macrovascular complications.

Listen to our multidisciplinary panel of experts as they discuss the prevention of CV events in patients with both type 2 diabetes and CVD, discussion will cover:

  • evidence-based strategies to reduce CV risk for patients with diabetes and CVD
  • advice on how to individualise choice of blood glucose-lowering agents
  • the latest Australian blood glucose treatment algorithm for type 2 diabetes
  • an update on the latest CV outcome trial data and how this impacts your practice.

Meet the panel

Dr Peter Piazza - webinar facilitator
Peter has been in general practice in the inner west of Sydney since 1977. Experiencing the growing diabetes epidemic among his patients, he developed an interest in how diabetes, associated with hypertension, dyslipidaemia and obesity, leads to CV and cerebrovascular disease. He is a member of the RACGP Diabetes Specific Interest Group. An engaging GP educator, Dr Piazza has been a regular guest on Drive Time Medical.

Dr Gary Deed
Gary is a Queensland GP with a passionate interest in promoting quality patient care for diabetes in general practice by supporting GP education, research and strategic collaboration. He is the National Chair of the RACGP Diabetes Specific Interest Network and a past president of Diabetes Australia. Dr Deed has contributed to diabetes management policies and guidelines, and published peer-reviewed articles on general practice management of diabetes. He is also involved in research on CVD and the elderly.

Elizabeth Obersteller
Elizabeth is a nurse practitioner and diabetes educator based in Wagga Wagga, NSW, with outreach throughout the district. Liz has worked with people with diabetes for over 21 years and has an interest in using collaboration and co-design principles to meet their needs. An active member of the Australian Diabetes Educators Association (ADEA), Liz is involved with the Agency for Clinical Innovation – Endocrine Network, and the National Association of Diabetes Centres.

Professor Sophia Zoungas
Sophia is a senior staff specialist in Endocrinology and Diabetes at Monash Health, Victoria, providing inpatient and outpatient care. She is a past president of the Australian Diabetes Society, Clinical Director of the National Association of Diabetes Centres and a director of Diabetes Australia. An internationally recognised clinical researcher in the fields of diabetes and CV health, she heads the Division of Metabolism, Ageing and Genomics in the School of Public Health and Preventive Medicine, Monash University. In this capacity she directs and supports projects and teaching on diabetes, CV health, healthy ageing and health care delivery.


Learning outcomes

On completion of this webinar you should be able to:

  • implement intensive cardiovascular risk factor management when treating patients with both type 2 diabetes and established cardiovascular disease (CVD)
  • select second- and third-line blood glucose-lowering medicines for patients with type 2 diabetes and established CVD based on patient and medicine factors
  • describe the data from new and emerging cardiovascular outcome trials and its relevance to practice
  • discuss your practice’s approach to prioritising improvement in the care of patients with type 2 diabetes and established CVD.